USRE47330E1 - Use of endovasclar hypothermia in organ and/or tissue transplantations - Google Patents
Use of endovasclar hypothermia in organ and/or tissue transplantations Download PDFInfo
- Publication number
- USRE47330E1 USRE47330E1 US11/351,216 US35121606A USRE47330E US RE47330 E1 USRE47330 E1 US RE47330E1 US 35121606 A US35121606 A US 35121606A US RE47330 E USRE47330 E US RE47330E
- Authority
- US
- United States
- Prior art keywords
- heat exchange
- donor
- temperature
- method according
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000000056 organs Anatomy 0 abstract claims description title 113
- 210000001519 tissues Anatomy 0 abstract claims description title 50
- 230000002631 hypothermal Effects 0 claims description title 18
- 239000000386 donor Substances 0 abstract claims description 82
- 206010021143 Hypoxia Diseases 0 abstract claims description 19
- 230000001146 hypoxic Effects 0 abstract claims description 19
- 230000037000 normothermia Effects 0 abstract claims description 11
- 230000003405 preventing Effects 0 abstract claims description 7
- 206010021113 Hypothermia Diseases 0 description title 13
- 210000004369 Blood Anatomy 0 claims description 42
- 239000008280 blood Substances 0 claims description 42
- 208000007204 Brain Death Diseases 0 claims description 34
- 210000002216 Heart Anatomy 0 claims description 32
- 210000003414 Extremities Anatomy 0 claims description 11
- 238000004891 communication Methods 0 claims description 10
- 210000001631 Vena Cava, Inferior Anatomy 0 claims description 9
- 210000003734 Kidney Anatomy 0 claims description 8
- 210000004204 Blood Vessels Anatomy 0 claims description 6
- 230000036757 core body temperature Effects 0 claims description 5
- 206010007515 Cardiac arrest Diseases 0 claims description 4
- 208000010496 Heart Arrest Diseases 0 claims description 4
- 210000000936 Intestines Anatomy 0 claims description 4
- 210000004185 Liver Anatomy 0 claims description 4
- 210000004072 Lung Anatomy 0 claims description 4
- 230000036760 body temperature Effects 0 claims description 4
- 241000282414 Homo sapiens Species 0 abstract description 3
- 230000000747 cardiac Effects 0 claims description 3
- 230000004044 response Effects 0 claims description 3
- 210000001185 Bone Marrow Anatomy 0 claims 2
- 210000000988 Bone and Bones Anatomy 0 claims 2
- 210000004087 Cornea Anatomy 0 claims 2
- 206010029216 Nervousness Diseases 0 claims 2
- 210000002435 Tendons Anatomy 0 claims 2
- 210000003371 Toes Anatomy 0 claims 2
- 210000003454 Tympanic Membrane Anatomy 0 claims 1
- 210000002620 Vena Cava, Superior Anatomy 0 claims 1
- 230000004064 dysfunctions Effects 0 claims 1
- 230000002977 hyperthermial Effects 0 claims 1
- 239000007787 solids Substances 0 claims 1
- 238000002054 transplantation Methods 0 description 13
- 238000001816 cooling Methods 0 description 12
- 238000010009 beating Methods 0 description 10
- 230000017531 blood circulation Effects 0 description 10
- 238000000034 methods Methods 0 description 9
- 230000000694 effects Effects 0 description 7
- 230000004087 circulation Effects 0 description 6
- 238000003780 insertion Methods 0 description 6
- 230000003247 decreasing Effects 0 description 5
- 239000003550 marker Substances 0 description 5
- 230000000702 anti-platelet Effects 0 description 4
- 239000003146 anticoagulant agent Substances 0 description 4
- 230000004217 heart function Effects 0 description 4
- 229920000139 polyethylene terephthalate Polymers 0 description 4
- 239000005020 polyethylene terephthalate Substances 0 description 4
- 210000004556 Brain Anatomy 0 description 3
- 206010049993 Cardiac death Diseases 0 description 3
- 230000037250 Clearance Effects 0 description 3
- 208000001953 Hypotension Diseases 0 description 3
- 210000000496 Pancreas Anatomy 0 description 3
- 230000001070 adhesive Effects 0 description 3
- 239000000853 adhesives Substances 0 description 3
- 230000035512 clearance Effects 0 description 3
- 239000003814 drug Substances 0 description 3
- 238000003306 harvesting Methods 0 description 3
- 230000036543 hypotension Effects 0 description 3
- 239000000463 materials Substances 0 description 3
- 238000005399 mechanical ventilation Methods 0 description 3
- 230000002829 reduced Effects 0 description 3
- 238000002689 xenotransplantation Methods 0 description 3
- 206010052779 Transplant rejections Diseases 0 description 2
- 230000001154 acute Effects 0 description 2
- 230000002411 adverse Effects 0 description 2
- 238000010276 construction Methods 0 description 2
- 239000000975 dyes Substances 0 description 2
- 230000002708 enhancing Effects 0 description 2
- 238000002156 mixing Methods 0 description 2
- 239000001301 oxygen Substances 0 description 2
- 229910052760 oxygen Inorganic materials 0 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound data:image/svg+xml;base64,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 data:image/svg+xml;base64,PD94bWwgdmVyc2lvbj0nMS4wJyBlbmNvZGluZz0naXNvLTg4NTktMSc/Pgo8c3ZnIHZlcnNpb249JzEuMScgYmFzZVByb2ZpbGU9J2Z1bGwnCiAgICAgICAgICAgICAgeG1sbnM9J2h0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnJwogICAgICAgICAgICAgICAgICAgICAgeG1sbnM6cmRraXQ9J2h0dHA6Ly93d3cucmRraXQub3JnL3htbCcKICAgICAgICAgICAgICAgICAgICAgIHhtbG5zOnhsaW5rPSdodHRwOi8vd3d3LnczLm9yZy8xOTk5L3hsaW5rJwogICAgICAgICAgICAgICAgICB4bWw6c3BhY2U9J3ByZXNlcnZlJwp3aWR0aD0nODVweCcgaGVpZ2h0PSc4NXB4JyA+CjwhLS0gRU5EIE9GIEhFQURFUiAtLT4KPHJlY3Qgc3R5bGU9J29wYWNpdHk6MS4wO2ZpbGw6I0ZGRkZGRjtzdHJva2U6bm9uZScgd2lkdGg9Jzg1JyBoZWlnaHQ9Jzg1JyB4PScwJyB5PScwJz4gPC9yZWN0Pgo8cGF0aCBjbGFzcz0nYm9uZC0wJyBkPSdNIDI1LjYwMjIsNDYuNzYyMSA1OC4zOTc4LDQ2Ljc2MjEnIHN0eWxlPSdmaWxsOm5vbmU7ZmlsbC1ydWxlOmV2ZW5vZGQ7c3Ryb2tlOiNGRjAwMDA7c3Ryb2tlLXdpZHRoOjJweDtzdHJva2UtbGluZWNhcDpidXR0O3N0cm9rZS1saW5lam9pbjptaXRlcjtzdHJva2Utb3BhY2l0eToxJyAvPgo8cGF0aCBjbGFzcz0nYm9uZC0wJyBkPSdNIDI1LjYwMjIsMzcuMjM3OSA1OC4zOTc4LDM3LjIzNzknIHN0eWxlPSdmaWxsOm5vbmU7ZmlsbC1ydWxlOmV2ZW5vZGQ7c3Ryb2tlOiNGRjAwMDA7c3Ryb2tlLXdpZHRoOjJweDtzdHJva2UtbGluZWNhcDpidXR0O3N0cm9rZS1saW5lam9pbjptaXRlcjtzdHJva2Utb3BhY2l0eToxJyAvPgo8dGV4dCB4PScxMC43NzY1JyB5PSc0OS45MzY5JyBzdHlsZT0nZm9udC1zaXplOjE1cHg7Zm9udC1zdHlsZTpub3JtYWw7Zm9udC13ZWlnaHQ6bm9ybWFsO2ZpbGwtb3BhY2l0eToxO3N0cm9rZTpub25lO2ZvbnQtZmFtaWx5OnNhbnMtc2VyaWY7dGV4dC1hbmNob3I6c3RhcnQ7ZmlsbDojRkYwMDAwJyA+PHRzcGFuPk88L3RzcGFuPjwvdGV4dD4KPHRleHQgeD0nNTguMzk3OCcgeT0nNDkuOTM2OScgc3R5bGU9J2ZvbnQtc2l6ZToxNXB4O2ZvbnQtc3R5bGU6bm9ybWFsO2ZvbnQtd2VpZ2h0Om5vcm1hbDtmaWxsLW9wYWNpdHk6MTtzdHJva2U6bm9uZTtmb250LWZhbWlseTpzYW5zLXNlcmlmO3RleHQtYW5jaG9yOnN0YXJ0O2ZpbGw6I0ZGMDAwMCcgPjx0c3Bhbj5PPC90c3Bhbj48L3RleHQ+Cjwvc3ZnPgo= O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0 description 2
- 230000002633 protecting Effects 0 description 2
- 241000894007 species Species 0 description 2
- 230000001225 therapeutic Effects 0 description 2
- 230000035899 viability Effects 0 description 2
- 206010060933 Adverse event Diseases 0 description 1
- 210000001367 Arteries Anatomy 0 description 1
- 241000237519 Bivalvia Species 0 description 1
- 206010061592 Cardiac fibrillation Diseases 0 description 1
- 210000001715 Carotid Arteries Anatomy 0 description 1
- 210000003191 Femoral Vein Anatomy 0 description 1
- 210000002837 Heart Atria Anatomy 0 description 1
- 241000282412 Homo Species 0 description 1
- 210000004153 Islets of Langerhans Anatomy 0 description 1
- 241001465754 Metazoa Species 0 description 1
- 208000010378 Pulmonary Embolism Diseases 0 description 1
- 210000002254 Renal Artery Anatomy 0 description 1
- 210000002796 Renal Veins Anatomy 0 description 1
- 208000010110 Spontaneous Platelet Aggregation Diseases 0 description 1
- 210000003462 Veins Anatomy 0 description 1
- 206010047281 Ventricular arrhythmia Diseases 0 description 1
- 230000010398 acute inflammatory response Effects 0 description 1
- 231100000494 adverse effects Toxicity 0 description 1
- 235000019994 cava Nutrition 0 description 1
- 235000020639 clam Nutrition 0 description 1
- 230000001934 delay Effects 0 description 1
- 230000001419 dependent Effects 0 description 1
- 230000018109 developmental process Effects 0 description 1
- 230000003203 everyday Effects 0 description 1
- 238000001125 extrusion Methods 0 description 1
- 230000002600 fibrillogenic Effects 0 description 1
- 238000002594 fluoroscopy Methods 0 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound data:image/svg+xml;base64,PD94bWwgdmVyc2lvbj0nMS4wJyBlbmNvZGluZz0naXNvLTg4NTktMSc/Pgo8c3ZnIHZlcnNpb249JzEuMScgYmFzZVByb2ZpbGU9J2Z1bGwnCiAgICAgICAgICAgICAgeG1sbnM9J2h0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnJwogICAgICAgICAgICAgICAgICAgICAgeG1sbnM6cmRraXQ9J2h0dHA6Ly93d3cucmRraXQub3JnL3htbCcKICAgICAgICAgICAgICAgICAgICAgIHhtbG5zOnhsaW5rPSdodHRwOi8vd3d3LnczLm9yZy8xOTk5L3hsaW5rJwogICAgICAgICAgICAgICAgICB4bWw6c3BhY2U9J3ByZXNlcnZlJwp3aWR0aD0nMzAwcHgnIGhlaWdodD0nMzAwcHgnID4KPCEtLSBFTkQgT0YgSEVBREVSIC0tPgo8cmVjdCBzdHlsZT0nb3BhY2l0eToxLjA7ZmlsbDojRkZGRkZGO3N0cm9rZTpub25lJyB3aWR0aD0nMzAwJyBoZWlnaHQ9JzMwMCcgeD0nMCcgeT0nMCc+IDwvcmVjdD4KPHRleHQgeD0nMTM4Ljk4OScgeT0nMTU3LjUnIHN0eWxlPSdmb250LXNpemU6MTVweDtmb250LXN0eWxlOm5vcm1hbDtmb250LXdlaWdodDpub3JtYWw7ZmlsbC1vcGFjaXR5OjE7c3Ryb2tlOm5vbmU7Zm9udC1mYW1pbHk6c2Fucy1zZXJpZjt0ZXh0LWFuY2hvcjpzdGFydDtmaWxsOiMwMDAwMDAnID48dHNwYW4+QXU8L3RzcGFuPjwvdGV4dD4KPC9zdmc+Cg== data:image/svg+xml;base64,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 [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0 description 1
- 239000010931 gold Substances 0 description 1
- 229910052737 gold Inorganic materials 0 description 1
- 239000002654 heat shrinkable material Substances 0 description 1
- 230000002949 hemolytic Effects 0 description 1
- 230000001939 inductive effects Effects 0 description 1
- 238000001802 infusion Methods 0 description 1
- 230000002401 inhibitory effects Effects 0 description 1
- 230000002427 irreversible Effects 0 description 1
- 239000007788 liquids Substances 0 description 1
- 230000000926 neurological Effects 0 description 1
- 230000000414 obstructive Effects 0 description 1
- 239000003973 paint Substances 0 description 1
- 230000000144 pharmacologic effect Effects 0 description 1
- 239000004033 plastic Substances 0 description 1
- 229920003023 plastics Polymers 0 description 1
- 200000000002 platelet activation Diseases 0 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound data:image/svg+xml;base64,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 data:image/svg+xml;base64,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 [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0 description 1
- 229910052697 platinum Inorganic materials 0 description 1
- 239000010932 platinum Substances 0 description 1
- -1 polyethylene terephthalate Polymers 0 description 1
- 238000004321 preservation Methods 0 description 1
- 230000001681 protective Effects 0 description 1
- 238000005086 pumping Methods 0 description 1
- 230000011514 reflex Effects 0 description 1
- 230000035812 respiration Effects 0 description 1
- 230000000241 respiratory Effects 0 description 1
- 230000029058 respiratory gaseous exchange Effects 0 description 1
- 235000013580 sausages Nutrition 0 description 1
- 238000007789 sealing Methods 0 description 1
- 230000002269 spontaneous Effects 0 description 1
- 238000001356 surgical procedure Methods 0 description 1
- 238000009423 ventilation Methods 0 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F7/12—Devices for heating or cooling internal body cavities
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F7/12—Devices for heating or cooling internal body cavities
- A61F2007/126—Devices for heating or cooling internal body cavities for invasive application, e.g. for introducing into blood vessels
Abstract
Description
This invention relates generally to methods for human or veterinary medical treatment and more particularly to a) the endovascular application of hypothermia to beating heart donors prior to harvesting of organ(s) and/or tissue(s) for transplantation to avoid hypoxic damage to the organ(s) and/or tissue(s) and b) the endovascular (e.g., intravascular) application of hypothermia to transplant recipients during and/or after transplantation of organ(s) and/or tissue(s) to reduce acute inflammatory response and help avoid acute transplant rejection and/or other complications.
In the early days of organ transplantation, all cadaveric (non-living) organ donors were pronounced dead by loss of heart function or “cardiac death” criteria. However, in the late 1960's and early 1970's “brain death” criteria were developed that allowed organs to be harvested from donors who's hearts were still beating but who had been pronounced dead based on the irreversible cessation of all brain activity. Additionally, it was learned that organ transplantation was more successful in cases where the donor's respiration and circulation were supported by artificial means (e.g., the use of mechanical ventilation and the administration of pharmacologic or mechanical support of cardiac activity) after brain death had occurred until the organs could be removed for transplantation. This “beating heart donor” technique enables oxygenated blood to continue to flow through the organs until immediately before they are harvested from the donor, thereby enhancing the organs' viability.
Every day, approximately ten people die in the United States while awaiting an organ transplant, simply because suitable donor organs are not available for them in time. Various approaches have been proposed for making transplantable organs more readily available to patients in need of transplants. For example, research is underway to develop genetically or immunologically modified animals who's organs may be suitable for xenotransplantation (i.e., transplantation of an organ or tissue from one species of animal into another species of animal) in humans. However, it remains uncertain as to whether xenotransplantation research will ultimately give rise to universally useable organs of all needed types and even if the current research is successful, the potential clinical implementation of xenotransplantation techniques remains many years away. Another approach has been to obtain some types of organs from human cadaveric donors who have been declared dead by traditional cardiac death criteria as opposed to brain death criteria. However, a number of important transplantable organs (e.g., hearts) can not typically be harvested from cadaveric donors more than just a few minutes after the cardiac death has occurred because the viability of the organ is lost.
On Jan. 6,2001 The United Network for Organ Sharing (UNOS) national patient waiting list for organ transplant included the following:
However, because of the shortage of suitable donor organs, the number of organ transplants that will actually be performed during the year 2001 is likely to be substantially lower than the number of patients on the waiting list. During the year 2000, the number of transplants actually performed in the United States were as follows:
Apart from the fact that the pool of potential organ donors is relatively small compared to the demand for transplantable organs, the shortage of organs is further exacerbated by the fact that sometimes, even after a potential donors family has agreed to organ donation, that donor's organs are lost because the donors cardiac activity can not be maintained for sufficient time to allow the necessary testing to establish and certify brain-death and to arrange for the arrival of the team of surgeons who are trained to remove the desired organ(s) from the donor's body. In view of these facts, there remains a need in the art for the development of new techniques to facilitate the harvesting of viable organs for transplantation so that more organs may be made available.
The present invention provides methods for decreasing the potential for hypoxic damage to transplantable organs in brain dead “beating heart” organ donors. The present invention also provides methods for preventing or treating episodes of acute transplant rejection in patients who have received organ or tissue transplants.
In accordance with one embodiment of the present invention, a heat exchange apparatus is inserted into the vasculature of a potential organ donor who is believed to be brain dead, but who has not yet been declared brain dead. The heat exchange apparatus is then used to cool the blood flowing through the potential donor's vasculature, thus cooling all of a portion of the donor's body to a desired temperature below normothermia (e.g., from about 37° C. to about 35° C. or less, often as low as 30°), thereby decreasing the oxygen demand of the tissues or organs to be transplanted and thus decreasing the likelihood that such tissues or organs will suffer hypoxic damage as a result of a hypoxic event while the patient is undergoing the necessary evaluation of his/her suitability as an organ donor, during the performance of testing necessary to confirm brain death (i.e., the “brain death work-up”) and until such time as brain death has been certified and any organs deemed suitable for transplantation have been harvested from the donor's body. The types of hypoxic events that may occur during this period of time include periods of cardiac arrest where the donor's heart ceases to beat for a period of time, periods of extreme hypotension or periods where the mechanical ventilation is inadvertently or purposely interrupted.
Further in accordance with the present invention, a heat exchange apparatus is may be inserted into the vasculature of a potential organ donor who has already been declared brain dead but from whose body the organs or tissues desired for transplantation have not yet been harvested. The heat exchange apparatus is then used to cool the blood flowing through the potential donor's vasculature, thus cooling all of a portion of the donor's body to a desired temperature below normothermia (e.g., from about 37° C. to about 35° C. or less), thereby decreasing the oxygen demand of the tissues or organs to be transplanted and thus decreasing the likelihood that such tissues or organs will suffer hypoxic damage as a result of a hypoxic event while the patient is undergoing the necessary evaluation of his/her suitability as an organ donor and until such time as brain death has been certified and any organs deemed suitable for transplantation have been harvested from the donor's body. The types of hypoxic events that may occur during this period of time include periods of cardiac arrest where the donor's heart ceases to beat for a period of time, periods of extreme hypotension or periods where the mechanical ventilation is inadvertently or purposely interrupted.
Still further in accordance with the present invention, the heat exchange apparatus may be a pliable or flexible structure that is formed or mounted and configured to expand when filled with thermal exchange fluid. One or more lumens may extend through the catheter to permit infusion or circulation of thermal exchange fluid through the heat exchange apparatus in situ. The catheter may be initially inserted into the vasculature of the donor or recipient patient using well known percutaneous catheter insertion techniques and the catheter may then be advanced through the vasculature to a position where the heat exchange apparatus is situated at a desired location. The heat exchange apparatus may comprise a balloon or inflatable structure that is attached to one or more lumens of the catheter such that cooled thermal exchange fluid may be infused into or circulated through the heat exchange apparatus in situ. Blood flowing in heat exchanging proximity to the heat exchange apparatus will thereby become cooled. The subsequent circulation of the cooled blood will then cool all or a selected portion of the donor's or patient's body to the desired temperature below normothermia. The core body temperature or the temperature of a particular body part or organ of the donor or patient may be monitored and the temperature of the heat exchange apparatus may be modified periodically or continuously in response to the monitored temperature to prevent significant overshoot beyond the desired temperature and to thereafter maintain the temperature of the body or portion thereof at the desired temperature or within a range of desired temperatures, such as about 33° C. to about 30° C. An automated controller may be connected to temperature sensor(s) used to monitor the core body temperature or the temperature of the desired organ or portion of the donor's or patient's body. Also, such controller may be operatively connected to an apparatus that changes the temperature of the thermal exchange fluid being circulated through the heat exchange apparatus and/or the rate at which such thermal exchange fluid is circulated through the heat exchange apparatus. Based on the signal(s) received from the temperature sensor(s), the controller will then modify the temperature and/or rate of the thermal exchange fluid to optimize the cooling and maintenance of the temperature of the donor's or patient's body or portion thereof.
Further aspects and advantages of the present invention will become apparent to those of skill in the art upon reading and understanding the detailed descriptions of certain embodiments of the invention set forth herebelow and in the accompanying drawings.
The following detailed description is provided for the purpose of describing only certain embodiments or examples of the invention and is not intended to describe all possible embodiments and examples of the invention.
Referring to
The catheter is attached at its proximal end to a hub 78. At the hub, the guide wire lumen 56 communicates with a guide wire port 80, the inflow lumen 52 is in fluid communication with an inflow port 82, and the outflow lumen 54 is in communication with an outflow port 84. Attached at the hub and surrounding the proximal shaft is a length of strain relief tubing 86 which may be, for example, a length of heat shrink tubing. The strain relief tubing may be provided with suture tie- downs 88, 90. Alternatively, a butterfly tie-down 92 may be provided. (See
Between the strain relief tubing 86 and the proximal end of the balloon 74, the shaft 50 is extruded with an outer diameter of about 0.118 inches. The internal configuration is as shown in cross-section in
At the necked down location 94, a proximal balloon marker band 102 is attached around the shaft. The marker band is a radiopaque material such as a platinum or gold band or radiopaque paint, and is useful for locating the proximal end of the balloon by means of fluoroscopy while the catheter is within the body of the patient.
At the location marked by the marker band, all four lobes of the balloon are reduced down and fastened around the inner member 67 in a fluid-tight seal. This may be accomplished by folding the outer lobes of the balloon 58, 60, 62 down around the inner lumen 64, placing a sleeve, for example a short length of tubing, snugly over the folded-down outer lumens of the balloon and inserting adhesive, for example by wicking the adhesive, around the entire inner circumference of the sleeve. The inner lumen is then fastened to the shaft using a second short length of tubing. The second short length for example 1 mm, of intermediate tubing 104 is heat welded to the inside of the inner lumen. The intermediate tube has an outer diameter approximately the same as the inner diameter of the inner lumen. The intermediate tube is then slid over the shaft at about the location of the neck-down region near the proximal marker 102, and adhesive 106 is wicked into the space between the inside of the intermediate tubing and the outer surface of the shaft 50. A similar process may be used to attach the distal end of the balloon, as will be described, except that the distal end of the balloon is attached down around the guide wire extension tube 98 rather than the shaft.
Just distal of the proximal balloon seal, under the balloon within the inner lumen, an elongated window 108 is cut through the wall of the outflow lumen in the shaft. Along the proximal portion of the balloon above this window, five slits, e.g. 110, are cut into the common wall between each of the outer lumens 58, 60, 62 and the inner lumen 64. Because the outer lumens are twined about the inner lumen in a helical fashion, each of the outer tubes passes over the outflow lumen of the inner shaft member at a slightly different location along the length of the inner shaft and, therefore, an elongated window 108 is cut into the outflow lumen of the shaft so that each outer lumen has at least one slit e.g. 110 that is located over the window in the shaft. Additionally, there is sufficient clearance between the outer surface of the shaft and the wall of the inner lumen to allow relatively unrestricted flow of heat exchange fluid through all 5 slits in each outer lumen, around the shaft, and through the elongate window 108 into the outflow lumen 54 in the shaft 50.
Distal of the elongated window in the outflow lumen, the inner lumen 64 of the four-lumen balloon is sealed around the shaft in a fluid tight plug. Referring to
Just distal of the plug, the outflow lumen is closed by means of a heat seal 99, and the inflow lumen is skived to form an opening 101 to the inner member. This may be accomplished by necking down the shaft at 96, attaching a guide wire extension tube 98 to the guide wire lumen, and simultaneously opening the inflow lumen 101 to the interior of the inner lumen and heat sealing the outflow lumen shut 101. The guide wire extension tube continues through the inner lumen, beyond the distal seal of the balloon (described below) to the distal end of the catheter 114 and thereby creates communication between the guide wire port 80 and the vessel distal of the catheter for using a guide wire to place the catheter or for infusing drugs, radiographic dye, or the like beyond the distal end of the catheter.
The distal end of the balloon 76 is sealed around the guide wire extension tube in essentially the same manner as the proximal end 74 is sealed down around the shaft. Just proximal of the distal seal, five slits 116 are cut into the common wall between each of the three outer lumens 58, 60 62 of the balloon and the inner lumen 64 so that each of the outer lumens is in fluid communication with the inner lumen.
Just distal of the balloon, near the distal seal, a distal marker band 118 is placed around the guide wire extension tube. A flexible length of tube 120 may be joined onto the distal end of the guide wire tube to provide a soft tip to the catheter as a whole.
In use, the catheter is inserted into the body of a patient so that the balloon is within a blood vessel, for example in the inferior vena cava (IVC). Heat exchange fluid is circulated into the inflow port 82, travels down the inflow lumen 52 and into the inner lumen 64 distal of the plug tube 112. The heat exchange fluid fills the inner lumen and travels down the inner lumen, thence through slits 116 between the inner lumen 64 and the three outer lumens 58, 60, 62.
The heat exchange fluid then travels back through the three outer lumens of the balloon to the proximal end of the balloon. Since outer lumens are wound in a helical pattern around the inner lumen, at some point along the length of the balloon near the proximal end and proximal of the plug, each outer lumen is located over the portion of the shaft having the window to the outflow lumen 108. There is also sufficient clearance between the wall of the inner lumen and the shaft, as illustrated in
Counter-current circulation between the blood and the heat exchange fluid is highly desirable for efficient heat exchange between the blood and the heat exchange fluid. Thus if the balloon is positioned in a vessel where the blood flow is in the direction from proximal toward the distal end of the catheter, for example if it were placed from the femoral vein into the Inferior Vena Cava (IVC) cava, it is desirable to have the heat exchange fluid in the outer balloon lumens flowing in the direction from the distal end toward the proximal end of the catheter. This is the arrangement described above. It is to be readily appreciated, however, that if the balloon were placed so that the blood was flowing along the catheter in the direction from distal to proximal, for example if the catheter was placed into the IVC from a jugular insertion, it would be desirable to have the heat exchange fluid circulate in the outer balloon lumens from the proximal end to the distal end. Although in the construction shown this is not optimal and would result is somewhat less effective circulation; this could be accomplished by reversing which port is used for inflow direction and which for outflow.
Where heat exchange fluid is circulated through the balloon that is colder than the blood in the vessel into which the balloon is located, heat will be exchanged between the blood and the heat exchange fluid through the outer walls of the outer lumens, so that heat is absorbed from the blood. If the temperature difference between the blood and the heat exchange fluid (sometimes called “ΔT”), for example if the blood of the patient is about 37° C. and the temperature of the heat exchange fluid is about 0° C., and if the walls of the outer lumens conduct sufficient heat, for example if they are of very thin (0.002 inches or less) plastic material such as polyethylene terephthalate (PET), enough heat may be exchanged (for example about 200 watts) to lower the blood temperature sufficiently to effect hypothermic anti-platelet activity, and to cool the temperature downstream of the catheter, for example of the heart, sufficiently for therapeutic inhibition of platelet activation, aggregation and/or adhesion. If the cooling catheter is left in place long enough for example for over half an hour, the entire body temperature of the patient may be cooled sufficiently for hypothermic anti-platelet activity. In this way, for example, blood to the brain and even the brain tissue itself may be cooled sufficiently for therapeutic hypothermic anti-platelet effect.
The helical structure of the outer lumens has the advantage over straight lumens of providing greater length of heat exchange fluid path for each length of the heat exchange region. This creates additional heat exchange surface between the blood and the heat exchange fluid for a given length of balloon. It may also provide for enhanced flow patterns for heat exchange between flowing liquids. The fact that the heat exchange region is in the form of an inflatable balloon also allows for a minimal insertion profile, for example 9 French or less, while the heat exchange region may be inflated once inside the vessel for maximum diameter of the heat exchange region in operation.
Automated control of the process is optional. Examples of apparatus and techniques that may be used for automated control of the process are described in U.S. pat. Nos. 6,149,673 and 6,149,676 and co-pending U.S. patent application Ser. No. 09/138,830, the entireties of which are expressly incorporated herein by reference.
Referring now to
Now with reference to
A fluid circulation path is illustrated by arrows in
A distal manifold of the heat exchange region 202 is shown and described with respect to
With this construction, heat exchange fluid introduced into the input port 240 will circulates through the inflow lumen 254, into the central lumen 222, out through the inflow lumen 254, into the central lumen 222, out through the apertures 280, and into the distal reservoir 282. From there, the heat exchange fluid will travel proximally through both intermediate lumens 226a, 226b and outer lumens 230a, 230b to the proximal reservoirs 274 and 275. Fluid then passes radially inwardly through the apertures 276 and port 278 into the outflow lumen 256. Then the fluid circulates back down the shaft 206 and out the of an outlet port 242.
The ribbon configuration of
The deflated profile of the heat exchange region is small enough to make an advantageous insertion profile, as small as 7 French for some applications. Even with this low insertion profile, the heat exchange region is efficient enough to adequately exchange heat with blood flowing past the heat exchange region to alter the temperature of the blood sufficient for anti-platelet action and affect the temperature of tissue downstream of the heat exchange region. Because of its smaller profile, it is possible to affect the temperature of blood in smaller vessels and thereby provide treatment to more localized body areas.
This configuration has a further advantage when the heat exchange region is placed in a tubular conduit such as a blood vessel, especially where the diameter of the vessel is approximately that of the major axis (width) of the cross section of the heat exchange region. The configuration tends to cause the heat exchange region to center itself in the middle of the vessel. This creates two roughly semicircular flow channels within the vessel, with the blood flow channels divided by the relatively flat ribbon configuration of the heat exchange region. It has been found that the means for providing maximum surface for heat exchange while creating minimum restriction to flow is this configuration, a relatively flat heat exchange surface that retains two approximately equal semi-circular cross-sections. This can be seen in reference to
B. Examples of Methods for Preventing Hypoxic Damage to Organs and Tissues in a Beating Heart Organ Donor:
In the example of
Additionally, even after the declaration or pronouncement of brain death has been made, there may be substantial further delays before the organs or tissues can be harvested from the donor's body. This is especially true in cases where a time-critical organ such as the heart has been matched to a recipient who is located far away from the donor and it is necessary to wait until a surgical team has been flown in from the recipient's location to perform the organ harvest and to then transport the critical organ to the location where the transplant surgery is to be conducted. Accordingly, in such cases, the provision of endovascular hypothermia even after the brain death declaration or pronouncement has been made may be beneficial in avoiding hypoxic damage to donor's the organs or tissues.
Moreover, a substantial period of time may be required before the brain death declaration or pronouncement may be made, as it is often necessary for heath care workers to locate and obtain written consent from the donor's family and to perform extensive tests and evaluations to confirm that the donor is in fact brain dead. The exact criteria by which brain death may be declared or pronounced may differ from state to state, country to country, or even institution to institution. In many jurisdictions, a declaration or pronouncement of brain death can only be made after numerous tests and evaluations have been completed (collectively referred to herein as the “brain death work-up”). These required tests and evaluations may include a clinical assessment to establish the lack of neurological responses and reflexes, hypoxia test(s) to confirm that the spontaneous respiratory drive is absent, and multiple electroencephalograms (EEGs) taken at time points separated by a prescribed waiting period (e.g., 24 hours). In at least some institutions, the declaration or pronouncement of brain death must be made by no fewer than two (2) physicians. Thus, the time period required to obtain the requisite consent and complete the entire brain death work up may span 48 hours or even longer. The provision of endovascular hypothermia during the brain death work up period in accordance with the method of
Specifically referring to the method of
In cases where it is desired to minimize or prevent cooling of portions of the body other than the selected body portion (e.g., a limb, organ or group of organs), a second heat exchange apparatus may be placed in one or more other blood vessels from which blood flows out of or away from the selected body portion (e.g., a limb, organ or group of organs) and the second heat exchange apparatus may be used to rewarm blood that flows out of or away from the selected body portion (e.g., a limb, organ or group of organs or blood flowing from the heart), thereby preventing the remainder of the body or at least the heart from becoming as hypothermic as the tissue or organ desired for transplantation. In this manner it is possible to cool the organ or tissue for transplantation well below the 25° C. temperature at which the heart begins to experience fibrillation or other adverse events, and yet keep the heart above that temperature to maintain effective cardiac function. For example, a first, cooling catheter might be placed in the renal artery to cool a kidney and a second warming catheter be placed in the renal vein or the IVC to warm blood returning from the kidneys to the heart. In fact, several additional catheters might be used, for example a cooling catheter might be placed in the artery for each kidney, and a warming catheter in each of the veins coming from the kidneys, and a warming catheter in IVC all to keep the heart warm enough to function effectively as a pump, and yet cool the target organ or tissue. This method of persevering organs or tissue is illustrated in the flow chart of
Although several illustrative examples of means for practicing the invention are described above, these examples are by no means exhaustive of all possible means for practicing the invention. The scope of the invention should therefore be determined with reference to the appended claims, along with the full range of equivalents to which those clams are entitled.
Claims (35)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/923,683 US6692519B1 (en) | 2001-08-06 | 2001-08-06 | Use of endovascular hypothermia in organ and/or tissue transplantations |
US11/351,216 USRE47330E1 (en) | 2001-08-06 | 2006-02-08 | Use of endovasclar hypothermia in organ and/or tissue transplantations |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/351,216 USRE47330E1 (en) | 2001-08-06 | 2006-02-08 | Use of endovasclar hypothermia in organ and/or tissue transplantations |
US11/725,845 US20070213793A1 (en) | 2001-08-06 | 2007-03-19 | Use of endovascular hypothermia in organ and/or tissue transplantations |
US11/725,845 USRE46697E1 (en) | 2001-08-06 | 2009-12-08 | Use of endovascular hypothermia in organ and/or tissue transplantations |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date | |
---|---|---|---|---|
US09/923,683 Reissue US6692519B1 (en) | 2001-08-06 | 2001-08-06 | Use of endovascular hypothermia in organ and/or tissue transplantations |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/923,683 Division US6692519B1 (en) | 2001-08-06 | 2001-08-06 | Use of endovascular hypothermia in organ and/or tissue transplantations |
US11/725,845 Division US20070213793A1 (en) | 2001-08-06 | 2007-03-19 | Use of endovascular hypothermia in organ and/or tissue transplantations |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE47330E1 true USRE47330E1 (en) | 2019-04-02 |
Family
ID=31188984
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/923,683 Active 2021-09-24 US6692519B1 (en) | 2001-08-06 | 2001-08-06 | Use of endovascular hypothermia in organ and/or tissue transplantations |
US11/351,216 Active USRE47330E1 (en) | 2001-08-06 | 2006-02-08 | Use of endovasclar hypothermia in organ and/or tissue transplantations |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/923,683 Active 2021-09-24 US6692519B1 (en) | 2001-08-06 | 2001-08-06 | Use of endovascular hypothermia in organ and/or tissue transplantations |
Country Status (1)
Country | Link |
---|---|
US (2) | US6692519B1 (en) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8128595B2 (en) * | 1998-04-21 | 2012-03-06 | Zoll Circulation, Inc. | Method for a central venous line catheter having a temperature control system |
US6338727B1 (en) * | 1998-08-13 | 2002-01-15 | Alsius Corporation | Indwelling heat exchange catheter and method of using same |
US6929656B1 (en) | 2001-09-14 | 2005-08-16 | Medcool, Inc. | Method and device for reducing secondary brain injury |
US7144418B1 (en) * | 2001-11-02 | 2006-12-05 | Medcool, Inc. | Method, and system for selective cerebral hypothermia |
US7156867B2 (en) * | 2001-12-31 | 2007-01-02 | Medcool, Inc. | Uniform selective cerebral hypothermia |
US7617005B2 (en) * | 2002-04-08 | 2009-11-10 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
CA2411569A1 (en) * | 2002-11-12 | 2004-05-12 | Ross E. Mantle | Medical device for the extravascular recirculation of fluid in body cavities at controlled temperature and pressure |
WO2004064622A2 (en) * | 2003-01-15 | 2004-08-05 | Medcool Inc. | Method and apparatus for managing temperature in a patient |
US20040199114A1 (en) * | 2003-04-01 | 2004-10-07 | Alsius Corporation | Intravascular heat exchange catheter with tissue preservative |
US20060064146A1 (en) * | 2004-09-17 | 2006-03-23 | Collins Kenneth A | Heating/cooling system for indwelling heat exchange catheter |
US8672988B2 (en) * | 2004-10-22 | 2014-03-18 | Medtronic Cryocath Lp | Method and device for local cooling within an organ using an intravascular device |
US7892269B2 (en) * | 2005-04-18 | 2011-02-22 | Zoll Circulation, Inc. | External heat exchange pad for patient |
US20060190066A1 (en) * | 2005-02-23 | 2006-08-24 | Worthen William J | System and method for bringing hypothermia rapidly onboard |
US20060190062A1 (en) * | 2005-02-23 | 2006-08-24 | Worthen William J | System and method for reducing shivering when using external cooling pads |
US7425216B2 (en) * | 2005-03-01 | 2008-09-16 | Alsius Corporation | System and method for treating cardiac arrest and myocardial infarction |
US7780712B2 (en) * | 2005-04-08 | 2010-08-24 | Jonathan Thomas | Laparoscopic kidney cooling device |
US20060276864A1 (en) * | 2005-06-03 | 2006-12-07 | Alsius Corporation | Systems and methods for sensing patient temperature in temperature management system |
EP1904151A4 (en) * | 2005-06-22 | 2011-06-22 | Univ Pittsburgh | Emergency preservation and resuscitation methods |
US20060293732A1 (en) * | 2005-06-27 | 2006-12-28 | Collins Kenneth A | Thermoelectric cooler (TEC) heat exchanger for intravascular heat exchange catheter |
US7181927B2 (en) * | 2005-07-01 | 2007-02-27 | Alsius Corporation | Primary heat exchanger for patient temperature control |
US7951182B2 (en) * | 2005-07-14 | 2011-05-31 | Zoll Circulation, Inc. | System and method for leak detection in external cooling pad |
US20070225781A1 (en) * | 2006-03-21 | 2007-09-27 | Nidus Medical, Llc | Apparatus and methods for altering temperature in a region within the body |
US7822485B2 (en) | 2006-09-25 | 2010-10-26 | Zoll Circulation, Inc. | Method and apparatus for spinal cooling |
US7867266B2 (en) | 2006-11-13 | 2011-01-11 | Zoll Circulation, Inc. | Temperature management system with assist mode for use with heart-lung machine |
US7892270B2 (en) * | 2006-11-21 | 2011-02-22 | Zoll Circulation Inc. | Temperature management system and method for burn patients |
US8353893B2 (en) | 2007-03-07 | 2013-01-15 | Zoll Circulation, Inc. | System and method for rapidly cooling cardiac arrest patient |
WO2008124643A1 (en) * | 2007-04-05 | 2008-10-16 | Velomedix, Inc. | Device and method for safe access to a body cavity |
EP2155300A1 (en) | 2007-04-05 | 2010-02-24 | Velomedix, Inc | Automated therapy system and method |
US9737692B2 (en) * | 2007-05-18 | 2017-08-22 | Zoll Circulation, Inc. | System and method for effecting non-standard fluid line connections |
US8439960B2 (en) * | 2007-07-09 | 2013-05-14 | Velomedix, Inc. | Hypothermia devices and methods |
JP2012508073A (en) * | 2008-11-07 | 2012-04-05 | ベロメディックス,インク | Apparatus and method for monitoring deep body temperature and intraperitoneal parameters |
CA2750473A1 (en) * | 2009-02-06 | 2010-08-12 | Velomedix, Inc. | Method and apparatus for inducing therapeutic hypothermia |
US9909783B2 (en) * | 2010-02-23 | 2018-03-06 | Robert Jensen | Twisted conduit for geothermal heat exchange |
US9622670B2 (en) | 2010-07-09 | 2017-04-18 | Potrero Medical, Inc. | Method and apparatus for pressure measurement |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4723939A (en) * | 1986-07-31 | 1988-02-09 | The Research Foundation Of State Univ. Of New York | Apparatus and method for multiple organ procurement |
WO1995011055A1 (en) | 1993-10-22 | 1995-04-27 | Scimed Lifesystems, Inc. | Improved stent delivery apparatus and method |
US5486208A (en) * | 1993-02-10 | 1996-01-23 | Ginsburg; Robert | Method and apparatus for controlling a patient's body temperature by in situ blood temperature modification |
US5709654A (en) * | 1990-10-10 | 1998-01-20 | Life Resuscitation Technologies, Inc. | Apparatus for cooling living tissue |
US5837003A (en) | 1993-02-10 | 1998-11-17 | Radiant Medical, Inc. | Method and apparatus for controlling a patient's body temperature by in situ blood temperature modification |
US6146411A (en) | 1998-12-24 | 2000-11-14 | Alsius Corporation | Cooling system for indwelling heat exchange catheter |
US6149670A (en) | 1999-03-11 | 2000-11-21 | Alsius Corporation | Method and system for treating cardiac arrest using hypothermia |
US6224624B1 (en) * | 1998-03-24 | 2001-05-01 | Innercool Therapies, Inc. | Selective organ cooling apparatus and method |
US6231594B1 (en) * | 1999-08-11 | 2001-05-15 | Radiant Medical, Inc. | Method of controlling body temperature while reducing shivering |
WO2001043661A2 (en) | 1999-12-14 | 2001-06-21 | Radiant Medical, Inc. | Method for reducing myocardial infarct by applicaton of intravascular hypothermia |
US6413233B1 (en) * | 1995-08-18 | 2002-07-02 | Biothermics, Inc. | Perfusion hyperthermia treatment system and method |
US6497721B2 (en) | 1993-02-10 | 2002-12-24 | Radiant Medical, Inc. | Method and apparatus for regional and whole body temperature modification |
-
2001
- 2001-08-06 US US09/923,683 patent/US6692519B1/en active Active
-
2006
- 2006-02-08 US US11/351,216 patent/USRE47330E1/en active Active
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4723939A (en) * | 1986-07-31 | 1988-02-09 | The Research Foundation Of State Univ. Of New York | Apparatus and method for multiple organ procurement |
US5709654A (en) * | 1990-10-10 | 1998-01-20 | Life Resuscitation Technologies, Inc. | Apparatus for cooling living tissue |
US5752929A (en) | 1990-10-10 | 1998-05-19 | Life Resuscitation Technologies, Inc. | Method of preserving organs other than the brain |
US6497721B2 (en) | 1993-02-10 | 2002-12-24 | Radiant Medical, Inc. | Method and apparatus for regional and whole body temperature modification |
US5486208A (en) * | 1993-02-10 | 1996-01-23 | Ginsburg; Robert | Method and apparatus for controlling a patient's body temperature by in situ blood temperature modification |
US5837003A (en) | 1993-02-10 | 1998-11-17 | Radiant Medical, Inc. | Method and apparatus for controlling a patient's body temperature by in situ blood temperature modification |
WO1995011055A1 (en) | 1993-10-22 | 1995-04-27 | Scimed Lifesystems, Inc. | Improved stent delivery apparatus and method |
US6413233B1 (en) * | 1995-08-18 | 2002-07-02 | Biothermics, Inc. | Perfusion hyperthermia treatment system and method |
US6224624B1 (en) * | 1998-03-24 | 2001-05-01 | Innercool Therapies, Inc. | Selective organ cooling apparatus and method |
US6620188B1 (en) * | 1998-08-24 | 2003-09-16 | Radiant Medical, Inc. | Methods and apparatus for regional and whole body temperature modification |
US6146411A (en) | 1998-12-24 | 2000-11-14 | Alsius Corporation | Cooling system for indwelling heat exchange catheter |
US6149670A (en) | 1999-03-11 | 2000-11-21 | Alsius Corporation | Method and system for treating cardiac arrest using hypothermia |
US6231594B1 (en) * | 1999-08-11 | 2001-05-15 | Radiant Medical, Inc. | Method of controlling body temperature while reducing shivering |
WO2001043661A2 (en) | 1999-12-14 | 2001-06-21 | Radiant Medical, Inc. | Method for reducing myocardial infarct by applicaton of intravascular hypothermia |
Also Published As
Publication number | Publication date |
---|---|
US6692519B1 (en) | 2004-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Waites et al. | Relation of vascular heat exchange to temperature regulation in the testis of the ram | |
US3140716A (en) | Heat exchanger for blood | |
US6685733B1 (en) | Methods and systems for reducing substance-induced renal damage | |
US6818011B2 (en) | Circulating fluid hypothermia method and apparatus | |
US7494504B2 (en) | Methods and apparatus for regional and whole body temperature modification | |
US6398752B1 (en) | Method of occluding a patient's ascending aorta and delivery cardioplegic fluid | |
US6786218B2 (en) | Medical procedure | |
US7008444B2 (en) | Method of controlling body temperature while reducing shivering | |
US6110168A (en) | Method and apparatus for controlling a patient's body temperature by in situ blood temperature modifications | |
US6458150B1 (en) | Method and apparatus for patient temperature control | |
US4416281A (en) | Surgical cushion for cooling an organ | |
KR100267604B1 (en) | Plasma-like solution | |
EP1204368B1 (en) | Central venous catheter with heat exchange properties | |
US5486208A (en) | Method and apparatus for controlling a patient's body temperature by in situ blood temperature modification | |
US8911485B2 (en) | Devices, systems and methods for rapid endovascular cooling | |
US6699231B1 (en) | Methods and apparatus for perfusion of isolated tissue structure | |
AU734265B2 (en) | Urethral warming catheter | |
US7407487B2 (en) | Temperature sensing system with retrograde sensor | |
Sutherland et al. | The isolated blood and perfusion fluid perfused heart | |
US3425419A (en) | Method of lowering and raising the temperature of the human body | |
Murray et al. | Homologous aortic-valve-segment transplants as surgical treatment for aortic and mitral insufficiency | |
CA1229020A (en) | Medical catheter | |
AU762196B2 (en) | Circulatory support system and method of use for isolated segmental perfusion | |
CA2318084C (en) | Selective organ hypothermia method and apparatus | |
US6896663B2 (en) | Retrograde venous perfusion with isolation of cerebral circulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BAY CITY CAPITAL FUND IV, L.P., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HORIZON TECHNOLOGY FUNDING COMPANY LLC;REEL/FRAME:019781/0792 Effective date: 20070906 |
|
AS | Assignment |
Owner name: BAY CITY CAPITAL FUND IV L.P., CALIFORNIA Free format text: SECURITY AGREEMENT;ASSIGNOR:RADIANT MEDICAL, INC.;REEL/FRAME:019812/0192 Effective date: 20070907 |
|
AS | Assignment |
Owner name: ZOLL CIRCULATION, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RADIANT MEDICAL, INC.;BAY CITY CAPITAL FUND IV, L.P.;REEL/FRAME:020684/0535 Effective date: 20070918 |